Q-omics provides the consensus-scored S100P profile across patient tissues and cancer cell-line models. S100P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, S100P is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, S100P protein abundance shows 21,264 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, COAD, and GBM as cancer lineages where S100P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100P survival associations across molecular data types. S100P RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100P RNA expression–survival associations across cancer types. High S100P expression shows unfavorable associations in LUAD, SKCM, ACC and PAAD, but favorable associations in SCLC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for S100P RNA expression.
This table summarizes S100P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for S100P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100P shows lower tumor expression in KICH and higher tumor expression in COAD, LUAD, BRCA, PAAD and LIHC. The COAD box plot shows higher S100P RNA expression in tumor versus normal tissue (log2 FC = +4.441, t-test p < 0.001).
This table shows molecular features associated with S100P in patient tissues and cancer cell lines. In patient samples, S100P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, S100P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
